7.0.0.0 Ref­er­ences

  1. Knowl­er WC, Bar­rett-‍Con­nor E, Fowler SE, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. Re­duc­tion in the in­ci­dence of type 2 di­a­betes with lifestyle in­ter­ven­tion or met­formin. N Engl J Med 2002;346:393–403
  2. Gar­vey WT, Ryan DH, Henry R, et al. Pre­ven­tion of type 2 di­a­betes in sub­jects with predi­a­betes and metabol­ic syn­drome treat­ed with phen­ter­mine and top­i­ra­mate ex­tend­ed re­lease. Di­a­betes Care 2014;37:912–921
  3. Torg­er­son JS, Haupt­man J, Boldrin MN, Sjo¨stro¨m L. XENi­cal in the pre­ven­tion of Di­a­betes in Obese Sub­jects (XEN­DOS) study: a ran­dom­ized study of orli­s­tat as an ad­junct to lifestyle changes for the pre­ven­tion of type 2 di­a­betes in obese pa­tients. Di­a­betes Care 2004;27:155–161
  4. le Roux CW, As­trup A, Fu­jio­ka K, et al.; SCALE Obe­si­ty Predi­a­betes NN8022-1839 Study Group. 3 years of li­raglu­tide ver­sus place­bo for type 2 di­a­betes risk re­duc­tion and weight man­age­ment in in­di­vid­u­als with predi­a­betes: a ran­domised, dou­ble-‍blind trial. Lancet 2017;389:1399–1409
  5. Booth H, Khan O, Pre­vost T, et al. In­ci­dence of type 2 di­a­betes after bariatric surgery: pop­u­la­tion-‍based matched co­hort study. Lancet Di­a­betes En­docrinol 2014;2:963–968
  6. UKPDS Group. UK Prospec­tive Di­a­betes Study 7: re­sponse of fast­ing plas­ma glu­cose to diet ther­a­py in newly pre­senting type II di­a­bet­ic pa­tients. Metabolism 1990;39:905–912
  7. Gold­stein DJ. Beneficial health ef­fects of mod­est weight loss. Int J Obes Relat Metab Dis­ord 1992;16:397–415
  8. Pas­tors JG, War­shaw H, Daly A, Franz M, Kulka­rni K. The ev­i­dence for the ef­fec­tiveness of med­i­cal nu­tri­tion ther­a­py in di­a­betes man­age­ment. Di­a­betes Care 2002;25:608–613
  9. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Math­ers JC, Tay­lor R. Re­ver­sal of type 2 di­a­betes: nor­mal­i­sa­tion of beta cell func­tion in as­so­ci­a­tion with de­creased pan­creas and liver tri­a­cyl­glyc­erol. Di­a­betolo­gia 2011;54:2506–2514
  10. Jack­ness C, Kar­mal­ly W, Febres G, et al. Very low-‍calo­rie diet mim­ics the early beneficial ef­fect of Roux-‍en-‍Y gas­tric by­pass on in­sulin sen­si­tiv­i­ty and b-cell func­tion in type 2 di­a­bet­ic pa­tients. Di­a­betes 2013;62:3027–3032
  11. Roth­berg AE, McEwen LN, Kraft­son AT, Fowler CE, Her­man WH. Very-low-en­er­gy diet for type 2 di­a­betes: an un­der­uti­lized ther­a­py? J Di­a­betes Com­pli­ca­tions 2014;28:506–510
  12. Hol­lan­der PA, El­bein SC, Hirsch IB, et al. Role of orli­s­tat in the treat­ment of obese pa­tients with type 2 di­a­betes: a 1-year ran­dom­ized dou­ble­blind study. Di­a­betes Care 1998;21:1288–1294
  13. Gar­vey WT, Ryan DH, Bo­han­non NJV, et al. Weight-‍loss ther­a­py in type 2 di­a­betes: ef­fects of phen­ter­mine and top­i­ra­mate ex­tend­ed re­lease. Di­a­betes Care 2014;37:3309–3316
  14. O’Neil PM, Smith SR, Weiss­man NJ, et al. Ran­dom­ized place­bo-‍con­trolled clin­i­cal trial of lor­caserin for weight loss in type 2 di­a­betes mel­li­tus: the BLOOM-‍DM study. Obe­si­ty (Sil­ver Spring) 2012;20:1426–1436
  15. Hol­lan­der P, Gupta AK, Plod­kows­ki R, et al.; COR-‍Di­a­betes Study Group. Ef­fects of nal­trex­one sus­tained-‍re­lease/bupropion sus­tained-‍re­lease com­bi­na­tion ther­a­py on body weight and glycemic pa­ram­e­ters in over­weight and obese pa­tients with type 2 di­a­betes. Di­a­betes Care 2013;36:4022–4029
  16. Davies MJ, Bergen­stal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of li­raglu­tide for weight loss among pa­tients with type 2 di­a­betes: the SCALE di­a­betes ran­dom­ized clin­i­cal trial. JAMA 2015;314:687–699
  17. Ru­bi­no F, Nathan DM, Eckel RH, et al.; Del­e­gates of the 2nd Di­a­betes Surgery Sum­mit. Metabol­ic surgery in the treat­ment al­go­rithm for type 2 di­a­betes: a joint state­ment by interna­tion­al di­a­betes or­ga­ni­za­tions. Di­a­betes Care 2016;39:861–877
  18. Day JW, Ot­t­away N, Pat­ter­son JT, et al. A new glucagon and GLP-1 co-‍ag­o­nist elim­i­nates obe­si­ty in ro­dents. Nat Chem Biol 2009;5:749–757
  19. Steven S, Hollingsworth KG, Al-‍Mrabeh A, et al. Very low-‍calo­rie diet and 6 months of weight sta­bil­i­ty in type 2 di­a­betes: patho­phys­i­o­log­i­cal changes in re­spon­ders and nonre­spon­ders. Di­a­betes Care 2016;39:808–815
  20. Schauer PR, Min­grone G, Ikra­mud­din S, Wolfe B. Clin­i­cal out­comes of metabol­ic surgery: efficacy of glycemic con­trol, weight loss, and re­mis­sion of di­a­betes. Di­a­betes Care 2016;39: 902–911
  21. Jensen MD, Ryan DH, Apo­vian CM, et al.; Amer­i­can Col­lege of Car­di­ology/Amer­i­can Heart As­so­ci­a­tion Task Force on Prac­tice Guide­lines; Obe­si­ty So­ci­ety. 2013 AHA/ACC/TOS guide­line for the man­age­ment of over­weight and obe­si­ty in adults: a re­port of the Amer­i­can Col­lege of Car­di­ology/Amer­i­can Heart As­so­ci­a­tion Task Force on Prac­tice Guide­lines and The Obe­si­ty So­ci­ety. J Am Coll Car­di­ol 2014;63(Suppl. 2): 2985–3023
  22. WHO Ex­pert Con­sul­ta­tion. Ap­pro­pri­ate body-‍mass index for Asian pop­u­la­tions and its im­pli­ca­tions for pol­i­cy and in­ter­ven­tion strate­gies. Lancet 2004;363:157–163
  23. Arane­ta MR, Grandinet­ti A, Chang HK. Op­ti­mum BMI cut points to screen Asian Amer­i­cans for type 2 di­a­betes: the UCSD Fil­ipino Health Study and the North Ko­ha­la Study (Ab­stract). Di­a­betes 2014;63(Suppl. 1):A20
  24. Roth­berg AE, McEwen LN, Kraft­son AT, et al. Im­pact of weight loss on waist cir­cum­fer­ence and the com­po­nents of the metabol­icsyn­drome. BMJ Open Di­a­betes Res Care 2017;5:e000341
  25. Lean ME, Leslie WS, Barnes AC, et al. Pri­ma­ry care-‍led weight man­age­ment for re­mis­sion of type 2 di­a­betes (Di­RECT): an open-‍label, cluster-ran­domised trial. Lancet 2018;391:541–551
  26. Wing RR, Bolin P, Bran­cati FL, et al.; Look AHEAD Re­search Group. Car­dio­vas­cu­lar ef­fects of in­ten­sive lifestyle in­ter­ven­tion in type 2 di­a­betes. N Engl J Med 2013;369:145–154
  27. Look AHEAD Re­search Group. Eight-‍year weight loss­es with an in­ten­sive lifestyle in­ter­ven­tion: the Look AHEAD study. Obe­si­ty (Sil­ver Spring) 2014;22:5–13
  28. Wild­ing JPH. The im­por­tance of weight man­age­ment in type 2 di­a­betes mel­li­tus. Int J Clin Pract 2014;68:682–691
  29. Baum A, Scarpa J, Bruzelius E, Tam­ler R, Basu S, Fagh­mous J. Tar­get­ing weight loss in­ter­ven­tions to re­duce car­dio­vas­cu­lar com­pli­ca­tions of type 2 di­a­betes: a ma­chine learn­ing-‍based post-‍hoc anal­y­sis of het­ero­ge­neous treat­ment ef­fects in the Look AHEAD trial. Lancet Di­a­betes En­docrinol 2017;5:808–815
  30. Franz MJ, Bouch­er JL, Rut­ten-‍Ramos S, Van­Wormer JJ. Lifestyle weight-‍loss in­ter­ven­tion out­comes in over­weight and obese adults with type 2 di­a­betes: a sys­tematic re­view and meta-‍anal­y­sis of ran­dom­ized clin­i­cal tri­als. J Acad Nutr Diet 2015;115:1447–1463
  31. Sacks FM, Bray GA, Carey VJ, et al. Com­par­i­son of weight-‍loss diets with dif­ferent com­po­si­tions of fat, pro­tein, and car­bo­hy­drates. N Engl J Med 2009;360:859–873
  32. de Souza RJ, Bray GA, Carey VJ, et al. Ef­fects of 4 weight-‍loss diets dif­fering in fat, pro­tein, and car­bo­hy­drate on fat mass, lean mass, vis­cer­al adi­pose tis­sue, and hep­at­ic fat: re­sults from the POUNDS LOST trial. Am J Clin Nutr 2012; 95:614–625
  33. John­ston BC, Kan­ters S, Ban­dayrel K, et al. Com­par­i­son of weight loss among named diet pro­grams in over­weight and obese adults: a meta-‍anal­y­sis. JAMA 2014;312:923–933
  34. Raynor HA, An­der­son AM, Miller GD, et al.; Look AHEAD Re­search Group. Par­tial meal re­place­ment plan and qual­i­ty of the diet at 1 year: Ac­tion for Health in Di­a­betes (Look AHEAD) Trial. J Acad Nutr Diet 2015;115:731–742
  35. Don­nel­ly JE, Blair SN, Ja­ki­cic JM, Manore MM, Rankin JW, Smith BK; Amer­i­can Col­lege of Sports Medicine. Ap­pro­pri­ate phys­i­cal ac­tiv­i­ty in­ter­ven­tion strate­gies for weight loss and pre­ven­tion of weight re­gain for adults. Med Sci Sports Exerc 2009;41:459–471
  36. Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of com­mer­cial weight-‍loss pro­grams: an up­dat­ed sys­tematic re­view. Ann In­tern Med 2015;162:501–512
  37. Tsai AG, Wad­den TA. The evo­lu­tion of very-low-‍calo­rie diets: an up­date and meta-‍anal­y­sis. Obe­si­ty (Sil­ver Spring) 2006;14:1283–1293
  38. Jo­hans­son K, Neovius M, Hem­mings­son E. Ef­fects of anti-‍obe­si­ty drugs, diet, and ex­er­cise on weight-‍loss main­te­nance after a very-low-‍calo­rie diet or low-‍calo­rie diet: a sys­tematic re­view and meta-‍anal­y­sis of ran­dom­ized con­trolled tri­als. Am J Clin Nutr 2014;99:14–23
  39. Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Base­line body mass index and the efficacy of hy­po­glycemic treat­ment in type 2 di­a­betes: a meta-‍anal­y­sis. PLoS One 2016;11:e0166625
  40. Domecq JP, Prut­sky G, Lep­pin A, et al. Clin­i­cal re­view: Drugs com­mon­ly as­so­ci­at­ed with weight change: a sys­tematic re­view and meta-‍anal­y­sis. J Clin En­docrinol Metab 2015;100:363–370
  41. Kahan S, Fu­jio­ka K. Obe­si­ty pharmacother­a­py in pa­tients with type 2 di­a­betes. Di­a­betes Spec­tr 2017;30:250–257
  42. Drugs.com. Phen­ter­mine [FDA pre­scrib­ing in­for­ma­tion] [In­ternet], 2017. Avail­able from: https://www.drugs.com/pro/phen­ter­mine.html. Ac­cessed 22 Septem­ber 2017
  43. Sul­li­van S. En­do­scop­ic med­i­cal de­vices for pri­ma­ry obe­si­ty treat­ment in pa­tients with di­a­betes. Di­a­betes Spec­tr 2017;30:258–264
  44. Sjo¨stro¨m L, Lin­droos A-K, Pel­to­nen M, et al.; Swedish Obese Sub­jects Study Sci­en­tific Group. Lifestyle, di­a­betes, and car­dio­vas­cu­lar risk fac­tors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683–2693
  45. Sjo¨stro¨m L, Pel­to­nen M, Ja­cob­son P, et al. As­so­ci­a­tion of bariatric surgery with long-‍term re­mis­sion of type 2 di­a­betes and with mi­crovas­cu­lar and macrovas­cu­lar com­pli­ca­tions. JAMA 2014;311:2297–2304
  46. Adams TD, David­son LE, Litwin SE, et al. Health benefits of gas­tric by­pass surgery after 6 years. JAMA 2012;308:1122–1131
  47. Sjo¨stro¨m L, Nar­bro K, Sjo¨stro¨m CD, et al.; Swedish Obese Sub­jects Study. Ef­fects of bariatric surgery on mor­tal­i­ty in Swedish obese sub­jects. N Engl J Med 2007;357:741–752
  48. Sjo¨stro¨m L, Gummes­son A, Sjo¨stro¨m CD, et al.; Swedish Obese Sub­jects Study. Ef­fects of bariatric surgery on can­cer in­ci­dence in obese pa­tients in Swe­den (Swedish Obese Sub­jects Study): a prospec­tive, con­trolled in­ter­ven­tion trial. Lancet Oncol 2009;10:653–662
  49. Sjo¨stro¨m L, Pel­to­nen M, Ja­cob­son P, et al. Bariatric surgery and long-‍term car­dio­vas­cu­lar events. JAMA 2012;307:56–65
  50. Adams TD, Gress RE, Smith SC, et al. Long-‍term mor­tal­i­ty after gas­tric by­pass surgery. N Engl J Med 2007;357:753–761
  51. Arter­burn DE, Olsen MK, Smith VA, et al. As­so­ci­a­tion be­tween bariatric surgery and long-‍term sur­vival. JAMA 2015;313:62–70
  52. Adams TD, Arter­burn DE, Nathan DM, Eckel RH. Clin­i­cal out­comes of metabol­ic surgery: mi­crovas­cu­lar and macrovas­cu­lar com­pli­ca­tions. Di­a­betes Care 2016;39:912–923
  53. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The long-‍term ef­fects of bariatric surgery on type 2 di­a­betes re­mis­sion, mi­crovas­cu­lar and macrovas­cu­lar com­pli­ca­tions, and mor­tal­i­ty: a sys­tematic re­view and meta-‍anal­y­sis. Obes Surg 2017;27:2724–2732
  54. Ru­bi­no F, Ka­plan LM, Schauer PR, Cum­mings DE; Di­a­betes Surgery Sum­mit Del­e­gates. The Di­a­betes Surgery Sum­mit con­sen­sus con­ference: rec­om­men­da­tions for the eval­u­a­tion and use of gas­troin­testi­nal surgery to treat type 2 di­a­betes mel­li­tus. Ann Surg 2010;251:399–405
  55. Cum­mings DE, Cohen RV. Be­yond BMI: the need for new guide­lines gov­ern­ing the use of bariatric and metabol­ic surgery. Lancet Di­a­betes En­docrinol 2014;2:175–181
  56. Zim­met P, Al­ber­ti KGMM, Ru­bi­no F, Dixon JB. IDF’s view of bariatric surgery in type 2 di­a­betes. Lancet 2011;378:108–110
  57. Kasama K, Mui W, Lee WJ, et al. IFSO-‍APC con­sen­sus state­ments 2011. Obes Surg 2012; 22:677–684
  58. Went­worth JM, Bur­ton P, Lau­rie C, Brown WA, O’Brien PE. Five-‍year out­comes of a ran­dom­ized trial of gas­tric band surgery in over­weight but not obese peo­ple with type 2 di­a­betes. Di­a­betes Care 2017;40:e44–e45
  59. Cum­mings DE, Arter­burn DE, West­brook EO, et al. Gas­tric by­pass surgery vs in­ten­sive lifestyle and med­i­cal in­ter­ven­tion for type 2 di­a­betes: the CROSS­ROADS ran­domised con­trolled trial. Di­a­betolo­gia 2016;59:945–953
  60. Liang Z, Wu Q, Chen B, Yu P, Zhao H, Ouyang X.Ef­fect of la­paro­scop­ic Roux-‍en-‍Y gas­tric by­pass surgery on type 2 di­a­betes mel­li­tus with hy­per­ten­sion: a ran­dom­ized con­trolled trial. Di­a­betes Res Clin Pract 2013;101:50–56
  61. Amini­an A, Chang J, Brethauer SA, Kim JJ; Amer­i­can So­ci­ety for Metabol­ic and Bariatric Surgery Clin­i­cal Is­sues Com­mit­tee. ASMBS up­dat­ed po­si­tion state­ment on bariatric surgery in class I obe­si­ty (BMI 30–35 kg/m2). Surg Obes Relat Dis 2018;14:1071–1087
  62. Isaman DJM, Roth­berg AE, Her­man WH. Rec­on­cil­i­a­tion of type 2 di­a­betes re­mis­sion rates in stud­ies of Roux-‍en-‍Y gas­tric by­pass. Di­a­betes Care 2016;39:2247–2253
  63. Ikra­mud­din S, Ko­rner J, Lee W-J, et al. Dura­bil­i­ty of ad­di­tion of Roux-‍en-‍Y gas­tric by­pass to lifestyle in­ter­ven­tion and med­i­cal man­age­ment in achiev­ing pri­ma­ry treat­ment goals for uncon­trolled type 2 di­a­betes in mild to mod­er­ate obe­si­ty: a ran­dom­ized con­trol trial. Di­a­betes Care 2016;39:1510–1518
  64. Sjo¨holm K, Pa­junen P, Ja­cob­son P, et al. In­ci­dence and re­mis­sion of type 2 di­a­betes in re­la­tion to de­gree of obe­si­ty at base­line and year weight change: the Swedish Obese Sub­jects (SOS) study. Di­a­betolo­gia 2015;58: 1448–1453/li>

  65. Arter­burn DE, Bog­a­rt A, Sher­wood NE, et al. A mul­ti­site study of long-‍term re­mis­sion and re­lapse of type 2 di­a­betes mel­li­tus fol­low­ing gas­tric by­pass. Obes Surg 2013;23:93–102

  66. Min­grone G, Pa­nun­zi S, De Gae­tano A, et al. Bariatric-‍metabol­ic surgery ver­sus con­ven­tion­al med­i­cal treat­ment in obese pa­tients with type 2 di­a­betes: 5 year fol­low-‍up of an open-‍label, sin­gle-‍cen­tre, ran­domised con­trolled trial. Lancet 2015;386:964–973
  67. Schauer PR, Bhatt DL, Kir­wan JP, et al.; STAM­PEDE In­ves­ti­ga­tors. Bariatric surgery ver­sus in­ten­sive med­i­cal ther­a­py for di­a­betesd5- year out­comes. N Engl J Med 2017;376:641– 651
  68. Cohen RV, Pin­heiro JC, Schi­avon CA, Salles JE, Wa­jchen­berg BL, Cum­mings DE. Ef­fects of gas­tric by­pass surgery in pa­tients with type 2 di­a­betes and only mild obe­si­ty. Di­a­betes Care 2012;35: 1420–1428
  69. Brethauer SA, Amini­an A, Romero-‍Talama´s H, et al. Can di­a­betes be sur­gi­cally cured? Long-‍term metabol­ic ef­fects of bariatric surgery in obese pa­tients with type 2 di­a­betes mel­li­tus. Ann Surg 2013;258:628–636; dis­cus­sion 636–637
  70. Hsu C-C, Al­mu­laifi A, Chen J-C, et al. Ef­fect of bariatric surgery vs med­i­cal treat­ment on type 2 di­a­betes in pa­tients with body mass index lower than 35: five-‍year out­comes. JAMA Surg 2015; 150:1117–1124
  71. Schauer PR, Bhatt DL, Kir­wan JP, et al.; STAM­PEDE In­ves­ti­ga­tors. Bariatric surgery ver­sus in­ten­sive med­i­cal ther­a­py for di­a­betesd 3-year out­comes. N Engl J Med 2014;370: 2002–2013
  72. Hariri K, Gue­vara D, Ja­yaram A, Kini SU, Her­ron DM, Fer­nan­dez-‍Ranvier G. Preop­er­a­tive in­sulin ther­a­py as a mark­er for type 2 di­a­betes re­mis­sion in obese pa­tients after bariatric surgery. Surg Obes Relat Dis 2018;14:332–337
  73. Yu H, Di J, Bao Y, et al. Vis­cer­al fat area as a new pre­dictor of short-‍term di­a­betes re­mis­sion after Roux-‍en-‍Y gas­tric by­pass surgery in Chi­nese pa­tients with a body mass index less than 35 kg/m2. Surg Obes Relat Dis 2015;11:6–11
  74. O’Brien R, John­son E, Ha­neuse S, et al. Mi­crovas­cu­lar out­comes in pa­tients with di­a­betes after bariatric surgery ver­sus usual care: a matched co­hort study. Ann In­tern Med 2018; 169:300–310
  75. Halperin F, Ding S-A, Si­mon­son DC, et al. Roux-‍en-‍Y gas­tric by­pass surgery or lifestyle with in­ten­sive med­i­cal man­age­ment in pa­tients with type 2 di­a­betes: fea­si­bil­i­ty and 1-year re­sults of a ran­dom­ized clin­i­cal trial. JAMA Surg 2014; 149:716–726
  76. Kir­wan JP, Amini­an A, Kashyap SR, Bur­guera B, Brethauer SA, Schauer PR. Bariatric surgery in obese pa­tients with type 1 di­a­betes. Di­a­betes Care 2016;39:941–948
  77. Rubin JK, Hinrichs-‍Krapels S, Hes­keth R, Mar­tin A, Her­man WH, Ru­bi­no F. Iden­ti­fy­ing bar­ri­ers to ap­pro­pri­ate use of metabol­ic/ bariatric surgery for type 2 di­a­betes treat­ment: Pol­i­cy Lab re­sults. Di­a­betes Care 2016;39:954– 963
  78. Fouse T, Schauer P. The so­cioe­co­nom­ic im­pact of mor­bid obe­si­ty and fac­tors af­fecting ac­cess to obe­si­ty surgery. Surg Clin North Am 2016;96:669–679
  79. Flum DR, Belle SH, King WC, et al.; Lon­gi­tu­di­nal As­sess­ment of Bariatric Surgery (LABS) Con­sor­tium. Periop­er­a­tive safe­ty in the lon­gi­tu­di­nal as­sessment of bariatric surgery. N Engl J Med 2009;361:445–454
  80. Cour­coulas AP, Chris­tian NJ, Belle SH, et al.; Lon­gi­tu­di­nal As­sess­ment of Bariatric Surgery (LABS) Con­sor­tium. Weight change and health out­comes at 3 years after bariatric surgery among in­di­vid­u­als with se­vere obe­si­ty. JAMA 2013;310:2416–2425
  81. Arter­burn DE, Cour­coulas AP. Bariatric surgery for obe­si­ty and metabol­ic con­di­tions in adults. BMJ 2014;349:g3961
  82. Young MT, Geb­hart A, Phe­lan MJ, Nguyen NT. Use and out­comes of la­paro­scop­ic sleeve gas­trec­to­my vs la­paro­scop­ic gas­tric by­pass: anal­y­sis of the Amer­i­can Col­lege of Sur­geons NSQIP. J Am Coll Surg 2015;220:880–885
  83. Amini­an A, Brethauer SA, Kir­wan JP, Kashyap SR, Bur­guera B, Schauer PR. How safe is metabol­ic/di­a­betes surgery? Di­a­betes Obes Metab 2015;17:198–201
  84. Birk­mey­er NJO, Dim­ick JB, Share D, et al.; Michi­gan Bariatric Surgery Col­lab­o­ra­tive. Hos­pi­tal com­pli­ca­tion rates with bariatric surgery in Michi­gan. JAMA 2010;304:435–442
  85. Al­tieri MS, Yang J, Telem DA, et al. Lap band out­comes from 19,221 pa­tients across cen­ters and over a decade with­in the state of New York. Surg En­dosc 2016;30:1725–1732
  86. Hut­ter MM, Schirmer BD, Jones DB, et al. First re­port from the Amer­i­can Col­lege of Sur­geons Bariatric Surgery Cen­ter Net­work: la­paro­scop­ic sleeve gas­trec­to­my has mor­bidity and ef­fec­tiveness po­si­tioned be­tween the band and the by­pass. Ann Surg 2011;254:410–420; dis­cus­sion 420–422
  87. Nguyen NT, Slone JA, Nguyen X-MT, Hart­man JS, Hoyt DB. A prospec­tive ran­dom­ized trial of la­paro­scop­ic gas­tric by­pass ver­sus la­paro­scop­ic ad­justable gas­tric band­ing for the treat­ment of mor­bid obe­si­ty: out­comes, qual­i­ty of life, and costs. Ann Surg 2009;250:631–641
  88. Cour­coulas AP, King WC, Belle SH, et al. Seven-‍year weight tra­jec­to­ries and health out­comes in the Lon­gi­tu­di­nal As­sess­ment of Bariatric Surgery (LABS) Study. JAMA Surg 2018;153: 427–434
  89. Birk­mey­er JD, Finks JF, O’Reil­ly A, et al.; Michi­gan Bariatric Surgery Col­lab­o­ra­tive. Sur­gi­cal skill and com­pli­ca­tion rates after bariatric surgery. N Engl J Med 2013;369: 1434–1442
  90. Ser­vice GJ, Thomp­son GB, Ser­vice FJ, An­drews JC, Collazo-‍Clavell ML, Lloyd RV. Hyperin­sulinemic hy­po­glycemia with ne­sid­ioblas­to­sis after gas­tric-‍by­pass surgery. N Engl J Med 2005;353:249–254
  91. Me­chan­ick JI, Kush­ner RF, Sug­er­man HJ, et al.; Amer­i­can As­so­ci­a­tion of Clin­i­cal En­docrinologists; Obe­si­ty So­ci­ety; Amer­i­can So­ci­ety for Metabol­ic & Bariatric Surgery. Amer­i­can As­so­ci­a­tion of Clin­i­cal En­docrinologists, The Obe­si­ty So­ci­ety, and Amer­i­can So­ci­ety for Metabol­ic & Bariatric Surgery med­i­cal guide­lines for clin­i­cal prac­tice for the periop­er­a­tive nu­tri­tion­al, metabol­ic, and nonsur­gi­cal sup­port of the bariatric surgery pa­tient. Obe­si­ty (Sil­ver Spring) 2009;17 (Suppl. 1):S1–S70
  92. Me­chan­ick JI, Youdim A, Jones DB, et al.; Amer­i­can As­so­ci­a­tion of Clin­i­cal En­docrinologists; Obe­si­ty So­ci­ety; Amer­i­can So­ci­ety for Metabol­ic & Bariatric Surgery. Clin­i­cal prac­tice guide­lines for the periop­er­a­tive nu­tri­tion­al, metabol­ic, and nonsur­gi­cal sup­port of the bariatric surgery pa­tientd2013 up­date: cospon­sored by Amer­i­can As­so­ci­a­tion of Clin­i­cal En­docrinologists, The Obe­si­ty So­ci­ety, and Amer­i­can So­ci­ety for Metabol­ic & Bariatric Surgery. Obe­si­ty (Sil­ver Spring) 2013;21(Suppl. 1):S1–S27
  93. Lee CJ, Clark JM, Schweitzer M, et al. Preva­lence of and risk fac­tors for hy­po­glycemic symp­toms after gas­tric by­pass and sleeve gas­trec­to­my. Obe­si­ty (Sil­ver Spring) 2015;23:1079–1084
  94. Cona­son A, Teix­eira J, Hsu C-H, Puma L, Knafo D, Geliebter A. Sub­stance use fol­low­ing bariatric weight loss surgery. JAMA Surg 2013;148:145– 150
  95. Bhat­ti JA, Na­thens AB, Thiruchel­vam D, Grantcharov T, Gold­stein BI, Re­delmeier DA. Self-‍harm emer­gen­cies after bariatric surgery: a pop­u­la­tion-‍based co­hort study. JAMA Surg 2016;151:226–232
  96. Pe­ter­ha¨nsel C, Petroff D, Klin­itzke G, Ker­st­ing A, Wag­n­er B. Risk of com­plet­ed sui­cide after bariatric surgery: a sys­tematic re­view. Obes Rev 2013;14:369–382
  97. Jakob­sen GS, Sma˚stuen MC, Sand­bu R, Nord­strand N, Hofsø D, Lind­berg M, et al. As­so­ci­a­tion of bariatric surgery vs med­i­cal obe­si­ty treat­ment with long-‍term med­i­cal com­pli­ca­tions and obe­si­ty-‍re­lat­ed co­mor­bidities. JAMA 2018; 319:291–301
  98. Young-‍Hyman D, Pey­rot M. Psy­choso­cial Care for Peo­ple with Di­a­betes. Alexan­dria, VA, Amer­i­can Di­a­betes As­so­ci­a­tion, 2012
  99. Green­berg I, Sogg S, M Perna F. Be­hav­ioral and psy­cho­log­i­cal care in weight loss surgery: best prac­tice up­date. Obe­si­ty (Sil­ver Spring) 2009;17:880–884
  100. Tru­ven Health An­a­lyt­ics. In­tro­duc­tion to RED BOOK On­line [In­ternet], 2013. Avail­able from http://www.mi­cromedex­so­lu­tions.com/ mi­cromedex2/4.34.0/‍WebHelp/‍RED_BOOK/ In­tro­duc­tion_to_REDB_BOOK_On­line.htm. Ac­cessed 5 Septem­ber 2018
  101. Data.Med­i­caid.gov. NADAC (Na­tion­al Av­er­age Drug Ac­qui­si­tion Cost) [In­ternet], 2018. Avail­able from https:/‍/‍data.med­i­caid.gov/Drug-‍ Pricing-and-Payment/NADAC-Na­tion­al-Av­er­age- Drug-‍Ac­qui­si­tion-‍Cost-‍/a4y5-998d. Ac­cessed 5 Septem­ber 2018
  102. U.S. Na­tion­al Li­brary of Medicine. Phen­ter­mine - phen­ter­mine hy­drochlo­ride cap­sule [In­ternet], 2017. Avail­able from https:/‍/‍dailymed.nlm.nih.gov/‍dailymed/‍drugInfo.cfm?setid5737eef3b- 9a6b-4ab3-a25c-49d84d2a0197. Ac­cessed 12 Septem­ber 2018
  103. Nal­pro­pi­on Phar­ma­ceu­ti­cals. Con­trave (nal­trex­one HCl/‍bupropion HCl) ex­tend­edre­lease tablets [pre­scrib­ing in­for­ma­tion] [In­ternet], 2018. Avail­able from https:/‍/‍contrave.com. Ac­cessed 12 Septem­ber 2018
  104. CHEP­LAPHARM, H2-‍Phar­ma. Xeni­cal (orli­s­tat) cap­sules [pre­scrib­ing in­for­ma­tion] [In­ternet]. Avail­able from https:/‍/‍xenical.com. Ac­cessed 12 Septem­ber 2018
  105. Eisai Inc. Belviq (lor­caserin HCl) tablets [pre­scrib­ing in­for­ma­tion] [In­ternet], 2016. Avail­able from https://www.belviq.com. Ac­cessed 12 Septem­ber 2018
  106. VIVUS, Inc. Qsymia (phen­ter­mine and top­i­ra­mate ex­tend­ed-‍re­lease) cap­sules [pre­scrib­ing in­for­ma­tion] [In­ternet], 2018. Avail­able from https:/‍/‍qsymia.com. Ac­cessed 12 Septem­ber 2018
  107. Novo Nordisk Inc. Sax­en­da (li­raglu­tide) in­jec­tion [pre­scrib­ing in­for­ma­tion] [In­ternet], 2018. Avail­able from https://www.sax­en­da. com. Ac­cessed 12 Septem­ber 2018
  108. Aronne LJ, Wad­den TA, Pe­ter­son C, Winslow D, Odeh S, Gadde KM. Eval­u­a­tion of phen­ter­mine and top­i­ra­mate ver­sus phen­ter­mine/top­i­ra­mate ex­tend­ed-‍re­lease in obese adults. Obe­si­ty (Sil­ver Spring) 2013;21:2163– 2171
  109. Gadde KM, Al­li­son DB, Ryan DH, et al. Ef­fects of low-‍dose, con­trolled-‍re­lease, phen­ter­mine plus top­i­ra­mate com­bi­na­tion on weight and as­so­ci­at­ed co­mor­bidities in over­weight and obese adults (CON­QUER): a ran­domised, place­bo-‍con­trolled, phase 3 trial. Lancet 2011; 377:1341–1352